Sarepta Therapeutics, Inc. (SRPT)
18.13
-0.66
(-3.51%)
USD |
NASDAQ |
Aug 24, 16:00
18.13
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Gross Profit Margin (Quarterly) : 60.18% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.18% |
| March 31, 2026 | 83.67% |
| December 31, 2025 | 7.70% |
| September 30, 2025 | 57.63% |
| June 30, 2025 | 73.26% |
| March 31, 2025 | 80.19% |
| December 31, 2024 | 78.32% |
| September 30, 2024 | 78.27% |
| June 30, 2024 | 85.32% |
| March 31, 2024 | 85.66% |
| December 31, 2023 | 86.00% |
| September 30, 2023 | 85.55% |
| June 30, 2023 | 82.81% |
| March 31, 2023 | 81.73% |
| December 31, 2022 | 84.00% |
| September 30, 2022 | 78.00% |
| June 30, 2022 | 79.58% |
| March 31, 2022 | 80.00% |
| December 31, 2021 | 79.21% |
| September 30, 2021 | 82.08% |
| June 30, 2021 | 82.96% |
| March 31, 2021 | 78.71% |
| December 31, 2020 | 79.54% |
| September 30, 2020 | 84.97% |
| June 30, 2020 | 85.57% |
| Date | Value |
|---|---|
| March 31, 2020 | 83.15% |
| December 31, 2019 | 84.25% |
| September 30, 2019 | 86.62% |
| June 30, 2019 | 82.96% |
| March 31, 2019 | 85.89% |
| December 31, 2018 | 84.18% |
| September 30, 2018 | 88.59% |
| June 30, 2018 | 90.55% |
| March 31, 2018 | 91.03% |
| December 31, 2017 | 93.43% |
| September 30, 2017 | 91.60% |
| June 30, 2017 | 93.49% |
| March 31, 2017 | 88.44% |
| December 31, 2016 | 66.91% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 0.00% |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Moderna, Inc. | -7.59% |
| ImmunityBio, Inc. | 90.82% |
| X4 Pharmaceuticals, Inc. | 81.24% |
| MapLight Therapeutics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -19.42% |
| Return on Assets | -7.88% |
| Return on Invested Capital | -10.58% |
| Profit Margin (Quarterly) | -1.22% |
| Operating Margin (Quarterly) | 13.03% |
| Return on Net Operating Assets | -13.22% |